↓ Skip to main content
What is this page? Embed badge

Long-acting beta2-agonists for chronic obstructive pulmonary disease

Overview of attention for article published in Cochrane database of systematic reviews, October 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news
2 news outlets
blogs
2 blogs
twitter
15 tweeters
facebook
1 Facebook page
googleplus
2 Google+ users

Citations

dimensions_citation
119 Dimensions

Readers on

mendeley
283 Mendeley
Summary News Blogs Twitter Facebook Google+ Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long-acting beta2-agonists for chronic obstructive pulmonary disease
Published in
Cochrane database of systematic reviews, October 2013
DOI 10.1002/14651858.cd010177.pub2
Pubmed ID
24127118
Authors

Kayleigh M Kew, Chris Mavergames, Julia AE Walters

Abstract

Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and mucus build-up. It is the fourth or fifth most common cause of death worldwide and is associated with significant healthcare costs.Inhaled long-acting beta2-agonists (LABAs) are widely prescribed to manage the symptoms of COPD when short-acting agents alone are no longer sufficient. Twice-daily treatment with an inhaled LABA is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline and even improving lung function and preventing and treating exacerbations.

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 15 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 283 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
United States 1 <1%
Netherlands 1 <1%
South Africa 1 <1%
Unknown 278 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 44 16%
Student > Ph. D. Student 32 11%
Student > Bachelor 30 11%
Researcher 29 10%
Other 24 8%
Other 55 19%
Unknown 69 24%
Readers by discipline Count As %
Medicine and Dentistry 116 41%
Nursing and Health Professions 24 8%
Pharmacology, Toxicology and Pharmaceutical Science 15 5%
Psychology 14 5%
Social Sciences 12 4%
Other 26 9%
Unknown 76 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 38. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 September 2022.
All research outputs
#949,401
of 23,577,761 outputs
Outputs from Cochrane database of systematic reviews
#2,056
of 12,746 outputs
Outputs of similar age
#8,979
of 212,624 outputs
Outputs of similar age from Cochrane database of systematic reviews
#42
of 211 outputs
Altmetric has tracked 23,577,761 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,746 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.1. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,624 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 211 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.

This page is provided by Altmetric.